Using prospective cohorts of health care personnel, first responders, and other essential and frontline workers* in eight U.S. Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials ( 1, 2) however, the benefits of these vaccines for preventing asymptomatic and symptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered in real-world conditions, is less well understood. Fry, MD 1 Manjusha Gaglani, MBBS 9 ,11 ( View author affiliations) View suggested citation Arvay, PhD 1 Preeta Kutty, MD 1 Alicia M. ![]() Morrill, MS 7 Josephine Mak, MPH 1 Patrick Rivers, MPP 2 Katherine M. Herring, MPH 7 Gregory Joseph, MPH 1 Shawn Beitel, MSc 2 Tyler C. Wesley, MPH 7 Julie Mayo Lamberte, MSPH 1 Xiaoxiao Sun, PhD 2 Michael E. Edwards, MPH 7 Natasha Schaefer-Solle, PhD 8 Lauren Grant, MS 1 Katherine Ellingson, PhD 2 Holly C. Hegmann, MD 5 Elisha Stefanski 6 Laura J. Kuntz, PhD 3 Kayan Dunnigan, MPH 9 Marilyn J. Caban-Martinez, DO 8 Ashley Fowlkes, ScD 1 Karen Lutrick, PhD 2 Jennifer L. Yoon, DO 5 Jennifer Meece, PhD 6 Lauren E.W.
0 Comments
Leave a Reply. |